Syndax Pharmaceuticals, Inc.

SNDX

$1.70B

Small Cap

NASDAQPharmaceutical Preparations🇺🇸North AmericaNEW YORK270 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Aug 5, 2026

25w

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

2 upcoming, 1 past

🎯PDUFANext

FDA PDUFA Date (standard)

8/5/2026

NDA filing. Extracted from SEC filing: 8-K

Source

Phase 2

Axatilimab Phase 2 Results Expected

September 2026~Axatilimab135

Primary completion for Axatilimab trial (NCT06132256) in Idiopathic Pulmonary Fibrosis

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Intensive Chemotherapy Regimen

Phase 3

Acute Myeloid Leukemias

Revumenib

Phase 3

Colorectal Cancer

entinostat

Phase 2

Non-Small Cell Lung Cancer

Aromatase Inhibitor (AI) Therapy

Phase 2

ER+ Breast Cancer

avelumab

Phase 2

Epithelial Ovarian Cancer

exemestane

Phase 2

Breast Cancer

cobicistat

Phase 2

Acute Myeloid Leukemia

Axatilimab

Phase 2

Chronic Graft-versus-host-disease

Erlotinib

Phase 2

Non-Small-Cell Lung Carcinoma

Drug Name	Phase	Indication	Designations
Intensive Chemotherapy Regimen	Phase 3	Acute Myeloid Leukemias	-
Revumenib	Phase 3	Colorectal Cancer	-
entinostat	Phase 2	Non-Small Cell Lung Cancer	-
Aromatase Inhibitor (AI) Therapy	Phase 2	ER+ Breast Cancer	-
avelumab	Phase 2	Epithelial Ovarian Cancer	-
exemestane	Phase 2	Breast Cancer	-
cobicistat	Phase 2	Acute Myeloid Leukemia	-
Axatilimab	Phase 2	Chronic Graft-versus-host-disease	-
Erlotinib	Phase 2	Non-Small-Cell Lung Carcinoma	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

SNDX News